Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.83 |
| ▸ | CNR1 | P21554 | 9/20 | 0.83 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.76 |
| ▸ | BCHE | P06276 | 4/20 | 0.73 |
| ▸ | ACHE | P22303 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5881674 | 0.88 | CNR2 (0.83) | CNR2CNR1OPRM1BCHEACHE | |
| SCHEMBL5881711 | 0.87 | CNR2 (1.00) | CNR2CNR1OPRM1BCHEACHE | |
| SCHEMBL5881820 | 0.87 | CNR2 (0.81) | CNR2CNR1OPRM1BCHEACHE | |
| SCHEMBL5881664 | 0.86 | CNR2 (1.00) | CNR2CNR1OPRM1BCHEACHE | |
| SCHEMBL5881746 | 0.86 | CNR2 (0.79) | CNR2CNR1OPRM1BCHEACHE | |
| SCHEMBL5881581 | 0.85 | CNR2 (0.85) | CNR2CNR1OPRM1BCHEACHE | |
| SCHEMBL5881875 | 0.85 | CNR2 (0.77) | CNR2CNR1OPRM1BCHEACHE | |
| SCHEMBL5881604 | 0.85 | CNR2 (0.77) | CNR2CNR1OPRM1BCHEACHE | |
| SCHEMBL5881940 | 0.84 | CNR2 (1.00) | CNR2CNR1OPRM1BCHEACHE | |
| SCHEMBL5881577 | 0.84 | CNR2 (1.00) | CNR2CNR1OPRM1BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135554-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | disclosed |
| US-7030139-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-04-18 | — | — | US | disclosed |
| US-20040116465-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| EP-1390350-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002085866-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135554-A1 | Novel compounds | OPRL1, OPRK1, TRPV1 | CNR2 21/4885CNR1 20/4885OPRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.